Member Publications

Members of the NASH Roundtable contribute important research to the public domain through peer-reviewed articles in medical journals. Below is a selection of recent research co-authored by Roundtable members. For a comprehensive search of NASH-related research by Roundtable members and others, visit pubmed.gov.

FacebookTwitterLinkedIn

A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.

Bosch J, Chung C, Carrasco-Zevallos OM, Harrison SA, Abdelmalek MF, Shiffman ML, Rockey DC, Shanis Z, Juyal D, Pokkalla H, Le QH, Resnick M, Montalto M, Beck AH, Wapinski I, Han L, Jia C, Goodman Z, Afdhal N, Myers RP, Sanyal AJ. Hepatology. 2021 Aug 1. doi: 10.1002/hep.32087.

View Publication »

Hepatic Fat Reduction Due to Resmetirom in Patients with Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life.

Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA. Clin Gastroenterol Hepatol. 2021 Jul 27:S1542-3565(21)00821-1. doi: 10.1016/j.cgh.2021.07.039.

View Publication »

Novel Antidiabetic Strategies and Diabetologists’ Views in Nonalcoholic Steatohepatitis.

Kahl S, Pützer J, Roden M. Semin Liver Dis. 2021 Jul 21. doi: 10.1055/s-0041-1732354.

View Publication »

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial.

Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O’Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Ratziu V, Gores GJ, Neuschwander-Tetri BA, Kemble G. Gastroenterology. 2021 Jul 20:S0016-5085(21)03276-5. doi: 10.1053/j.gastro.2021.07.025.

View Publication »

Risk difference of liver-related and cardiovascular events by liver fibrosis status in nonalcoholic fatty liver disease.

Tamaki N, Higuchi M, Kurosaki M, Loomba R, Izumi N; MRCH Liver Study Group, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Itakura J. Clin Gastroenterol Hepatol. 2021 Jul 16:S1542-3565(21)00752-7. doi: 10.1016/j.cgh.2021.07.021.

View Publication »

Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.

Younossi ZM, Stepanova M, Nader F, Loomba R, Anstee QM, Ratziu V, Harrison S, Sanyal AJ, Schattenberg JM, Barritt AS, Noureddin M, Bonacci M, Cawkwell G, Wong B, Rinella M; REGENERATE Study Investigators. Clin Gastroenterol Hepatol. 2021 Jul 15:S1542-3565(21)00751-5. doi: 10.1016/j.cgh.2021.07.020.

View Publication »

Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis.

Rivera-Esteban J, Armandi A, Augustin S, Bugianesi E.Liver Int. 2021 Jul 9. doi: 10.1111/liv.15013.

View Publication »

Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD.

Vilarinho S, Ajmera V, Zheng M, Loomba R. Hepatology. 2021 Jul 7. doi: 10.1002/hep.32047.

View Publication »

Preparing for the NASH epidemic: A call to action.

Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Metabolism. 2021 Jul 6:154822. doi: 10.1016/j.metabol.2021.154822.

View Publication »

PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH.

Gastaldelli A, Sabatini S, Carli F, Gaggini M, Bril F, Belfort-DeAguiar R, Positano V, Barb D, Kadiyala S, Harrison S, Cusi K. Liver Int. 2021 Jul 5. doi: 10.1111/liv.15005.

View Publication »

A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease.

Younossi ZM, Ong JP, Takahashi H, Yilmaz Y, Eguchi Y, El Kassas M, Buti M, Diago M, Zheng MH, Fan JG, Yu ML, Wai-Sun Wong V, Alswat K, Chan WK, Mendez-Sanchez N, Burra P, Bugianesi E, Duseja AK, George J, Papatheodoridis GV, Saeed H, Castera L, Arrese M, Kugelmas M, Romero-Gomez M, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. Clin Gastroenterol Hepatol. 2021 Jul 3:S1542-3565(21)00719-9. doi: 10.1016/j.cgh.2021.06.048.

View Publication »

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial.

Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O’Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Ratziu V, Gores GJ, Neuschwander-Tetri BA, Kemble G. 
Gastroenterology. 2021 Jul 20:S0016-5085(21)03276-5. doi: 10.1053/j.gastro.2021.07.025.

View Publication »

Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes.

Bril F, McPhaul MJ, Kalavalapalli S, Lomonaco R, Barb D, Gray ME, Shiffman D, Rowland CM, Cusi K. J Clin Endocrinol Metab. 2021 Jun 30:dgab417. doi: 10.1210/clinem/dgab417.

View Publication »

Defining comprehensive models of care for NAFLD.

Lazarus JV, Anstee QM, Hagström H, Cusi K, Cortez-Pinto H, Mark HE, Roden M, Tsochatzis EA, Wong VW, Younossi ZM, Zelber-Sagi S, Romero-Gómez M, Schattenberg JM. Nat Rev Gastroenterol Hepatol. 2021 Jun 25. doi: 10.1038/s41575-021-00477-7.

View Publication »

Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis.

Yu J, Zhu C, Wang X, Kim K, Bartolome A, Dongiovanni P, Yates KP, Valenti L, Carrer M, Sadowski T, Qiang L, Tabas I, Lavine JE, Pajvani UB. Sci Transl Med. 2021 Jun 23;13(599):eabe1692. doi: 10.1126/scitranslmed.abe1692.

View Publication »

Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease.

Zhou YJ, Gao F, Liu WY, Wong GL, Mahadeva S, Raihan Nik Mustapha N, Wang XD, Chan WK, Wong VW, Zheng MH. Aliment Pharmacol Ther. 2021 Jun 21. doi: 10.1111/apt.16487.

View Publication »

Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD.

Jiao N, Loomba R, Yang ZH, Wu D, Fang S, Bettencourt R, Lan P, Zhu R, Zhu L. Physiol Genomics. 2021 Jun 21. doi: 10.1152/physiolgenomics.00011.2021.

View Publication »

Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.

Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, Pennisi G, Liguori A, Francione P, Gallego-Durán R, Ampuero J, Garcia Blanco MJ, Aller R, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Pareja MJ, Zaki MYW, Grieco A, Fracanzani AL, Valenti L, Miele L, Fariselli P, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E. J Hepatol. 2021 Jun 3:S0168-8278(21)00343-3. doi: 10.1016/j.jhep.2021.05.008.

View Publication »

Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.

Dayton KA, Bril F, Barb D, Lai J, Kalavalapalli S, Cusi K. PLoS One. 2021 Jun 2;16(6):e0251449. doi: 10.1371/journal.pone.0251449.

View Publication »

Consensus scoring systems for nonalcoholic fatty liver disease: an unmet clinical need.

Zhou YJ, Wong VW, Zheng MH. Hepatobiliary Surg Nutr. 2021 Jun;10(3):388-390. doi: 10.21037/hbsn-21-80.

View Publication »

Non-alcoholic fatty liver disease in type 2 diabetes – A specific entity?

Schröder B, Kahl S, Roden M. Liver Int. 2021 Jun;41 Suppl 1:105-111. doi: 10.1111/liv.14846.

View Publication »

Natural history of NASH.

Armandi A, Bugianesi E. Liver Int. 2021 Jun;41 Suppl 1:78-82. doi: 10.1111/liv.14910.

View Publication »

Management of NAFLD patients with advanced fibrosis.

Maya-Miles D, Ampuero J, Gallego-Durán R, Dingianna P, Romero-Gómez M. Liver Int. 2021 Jun;41 Suppl 1:95-104. doi: 10.1111/liv.14847.PMID: 34155801

View Publication »

New drugs for NASH.

Albhaisi SAM, Sanyal AJ. Liver Int. 2021 Jun;41 Suppl 1:112-118. doi: 10.1111/liv.14844.

View Publication »

Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study.

Barritt AS, Watkins S, Gitlin N, Klein S, Lok AS, Loomba R, Schoen C, Reddy KR, Trinh HN, Mospan AR, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Hepatol Commun. 2021 Feb 21;5(6):938-946. doi: 10.1002/hep4.1689. eCollection 2021 Jun.

View Publication »

Read More »

Follow us on LinkedIn for publication updates